Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Human Genome Sciences Inc (HGSI), founded on 26th June 1992, is a mid-stage development biopharmaceutical company focused on therapeutic product development and functional analysis of genes using its proprietary technology platform. HGSI's goal is to build a global biopharmaceutical company that discovers, develops, manufactures and markets gene-based protein and antibody (Ab) drugs to treat and cure disease. The company focuses its internal product development efforts on novel human protein and Ab drugs discovered through genomics-based research, and on new long-acting versions of existing protein drugs created using its albumin fusion technology. HGSI uses collaborations for the development of other protein and Ab drugs, gene-therapy products, small-molecule drugs and diagnostic products discovered using its genomics-based technology.